Drug Profile
Pfs25-Pfs230 malaria vaccine - MVI
Alternative Names: Pfs230D1-EPA/Matrix-M Vaccine; PFS25 VLP & Pfs230 VLP; Pfs25-Pfs230 virus-like particle malaria vaccine - MVI; Pfs25/Alhydrogel and Pfs230D1M-EPA/Alhydrogel; Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01Latest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator Burnet Institute; Malaria Vaccine Initiative
- Developer National Institute of Allergy and Infectious Diseases
- Class Antimalarials; Parasitic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malaria
Most Recent Events
- 21 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with Novavax completes phase I trial (In adults, Prevention) in Mali (NCT05135273)
- 22 Oct 2021 National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with Novavax initiates phase I trial (In adults, Prevention) in Mali (NCT05135273)
- 29 Sep 2021 Pfs25-Pfs230 malaria vaccine is still in phase II trials for Malaria (In children, In adults, In the elderly, Prevention) in Mali (Parenteral) (NCT03917654)